Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$8.33
▲ $0.04 (+0.4%)
Market data updated: 09/21 02:22 PM
Fundamentals updated: 09/21/2026
News analyzed: 09/21/2026
Market Cap
$544.34M
Day Range
$8.27 - $8.44
52-Week Range
$6.97 - $14.51
Beta
—
Next Earnings
03.11.2026
Support
$7.90
Resistance
$9.74
ARVN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+7.4% (1Y)
Strengths: 10/29 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 58.8%
Growth
Biggest negative driver
Operating margin
Operating margin: -45.1% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
46
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $8.29
Evidence: Panic-selling score jumped from 4 to 33 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
54
Quality
63
Value
55
Momentum
26
Risk
46
Sentiment
74
Fundamental
34
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Arvinas, Inc. has centered on its participation in investor conferences, including the Wells Fargo and Cantor Global Healthcare events, highlighting its focus on investor engagement. The company also announced an inducement grant under Nasdaq listing rules, while prior reports emphasized the FDA approval of its drug Veppanu and a $50 million milestone from Pfizer, driving record net income in Q2 2026. Analysts have praised its PROTAC-based drug platform as a key strength.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Arvinas, Inc.. News trend score: 74. Reason: 5 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
29
🎯 Conviction (vs. Emotion)
42
Psychology
33
Fundamentals
34
Technical
26
Valuation
55
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price (3M)
+8%
Market Narrative
42
Fundamental Reality
42
Narrative Gap
+0
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant anchoring behavior reflects a stock trading near resistance (3.7% away), where investors may fixate on past highs despite weak momentum (-3.0% ROC) and neutral volume. Confirmation bias is also present, as the narrative-reality gap (+11) aligns with selective focus on improving margins while ignoring flat revenue. The absence of panic or herding suggests a cautious, non-emotional stance, though FOMO and euphoria remain muted by technical weakness. The key question is whether the stock can sustain momentum if it breaks resistance or if anchoring will persist as a barrier.
Updated: 09/08/2026, 07:53 AM
What could change this?
👥 What the crowd believes
"Veppanu’s FDA approval and a robust PROTAC platform"
"$50 million Pfizer milestone fuel record net income"
🧠 Market Brain events driving this
📈 5D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Jesse Livermore — 17/100
🗣️ Why do they disagree?
The scores for ARVN span from a perfect 100 down to 14, reflecting a wide divergence among the historic methodologies. Based on Walter Bagehot’s, Samuel Nelson’s and Benjamin Graham’s documented principles, the model estimates that the stock’s strong liquidity, favorable cycle position, and defensive value characteristics earn it high marks, while Charles Mackay’s view of no crowd mania adds further support. In contrast, investors such as Peter Lynch, the enterprising Graham, Howard Marks, Jack Schwager, Thorstein Veblen and Gerald Loeb, whose documented criteria blend growth prospects with valuation and risk considerations, assign mid‑range scores, indicating they see potential but also caution about price, risk and mixed signals. Finally, according to the documented standards of Edgar Lawrence Smith, the efficient‑market view of Malkiel & Bogle, Morgan Housel, Philip Fisher and Jesse Livermore, the model estimates that the stock lacks a clear long‑term edge, shows volatility that could deter patient holders, falls short of Fisher’s quality‑growth signature, and runs counter to Livermore’s trend rule, resulting in the lowest scores.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 96
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 93
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 86
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 73
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 71
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 69
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 68
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 66
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 56
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 48
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 47
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 21
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 17
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-45.1%
Net Margin
-30.8%
EBITDA Margin
—
ROE
-18.6%
ROA
-11.3%
ROIC
—
EPS
-$1.14
Cash
$142.90M
Total Debt
$600.00K
Current Ratio
4.92
Debt/Equity
0.00
How is Fair Value calculated? →
Current Price
$8.33
Estimated Fair Value (DCF)
-$97.21
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-344.63M | $-316.17M |
| 2 | 19.4% | $-411.40M | $-346.26M |
| 3 | 13.8% | $-467.96M | $-361.35M |
| 4 | 8.1% | $-505.99M | $-358.45M |
| 5 | 2.5% | $-518.63M | $-337.08M |
Base FCF (last actual year)
$-275.70M
Terminal Value
$-8.18B
Present Value of Terminal Value
$-5.32B
Enterprise Value
$-7.03B
Net Debt
$-142.30M
Equity Value
$-6.89B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$6.83
Tangible Book Value per Share (Tangible NAV)
$10.62
Sentiment based on basic keywords (not AI) — 5 positive, 14 neutral, 1 negative out of the last 20 articles.
Yahoo · 18.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 9.9.2026
Insider Monkey · 9.9.2026
GlobeNewswire · 3.9.2026
Yahoo · 3.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
SeekingAlpha · 28.8.2026
Motley Fool · 11.8.2026
Yahoo · 11.8.2026
MT Newswires · 10.8.2026
Yahoo · 10.8.2026
Benzinga · 10.8.2026
Benzinga · 10.8.2026
MT Newswires · 10.8.2026
Zacks · 6.8.2026
Arvinas, Inc. (ARVN) currently has a StockIQ AI score of 46/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ARVN currently scores 46/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
ARVN's technical score is 26/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 58.8%; Net income growth: 59.4%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: Operating margin: -45.1% (negative); Net margin: -30.8% (negative); ATR: 4.1% of price.
StockIQ has no recorded dividend payment history for ARVN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Saik Andrew | Open Market Sale | 24.6.2026 | 5,696 | -5,696 | $8.16 |
| Bain Linda | Grant/Award from Employer | 24.6.2026 | 22,714 | +22,714 | — |
| Bain Linda | Grant/Award from Employer | 24.6.2026 | 15,527 | +15,527 | — |
| Cunningham Everett | Grant/Award from Employer | 24.6.2026 | 22,714 | +22,714 | — |
| Cunningham Everett | Grant/Award from Employer | 24.6.2026 | 15,527 | +15,527 | — |
| Kennedy Edward Moore Jr. | Grant/Award from Employer | 24.6.2026 | 22,714 | +22,714 | — |
| Kennedy Edward Moore Jr. | Grant/Award from Employer | 24.6.2026 | 15,527 | +15,527 | — |
| Morrison Briggs | Grant/Award from Employer | 24.6.2026 | 22,714 | +22,714 | — |
| Norwalk Leslie V | Grant/Award from Employer | 24.6.2026 | 22,714 | +22,714 | — |
| Morrison Briggs | Grant/Award from Employer | 24.6.2026 | 15,527 | +15,527 | — |
| Smaldone Alsup Laurie | Grant/Award from Employer | 24.6.2026 | 22,714 | +22,714 | — |
| Norwalk Leslie V | Grant/Award from Employer | 24.6.2026 | 15,527 | +15,527 | — |
| Smaldone Alsup Laurie | Grant/Award from Employer | 24.6.2026 | 15,527 | +15,527 | — |
| Saik Andrew | Open Market Sale | 24.6.2026 | 187,432 | -5,696 | $8.16 |
| Norwalk Leslie V | Grant/Award from Employer | 24.6.2026 | 41,572 | +15,527 | — |
| Norwalk Leslie V | Grant/Award from Employer | 24.6.2026 | 22,714 | +22,714 | — |
| Cunningham Everett | Grant/Award from Employer | 24.6.2026 | 41,572 | +15,527 | — |
| Cunningham Everett | Grant/Award from Employer | 24.6.2026 | 22,714 | +22,714 | — |
| Bain Linda | Grant/Award from Employer | 24.6.2026 | 41,572 | +15,527 | — |
| Bain Linda | Grant/Award from Employer | 24.6.2026 | 22,714 | +22,714 | — |
| Smaldone Alsup Laurie | Grant/Award from Employer | 24.6.2026 | 41,572 | +15,527 | — |
| Smaldone Alsup Laurie | Grant/Award from Employer | 24.6.2026 | 22,714 | +22,714 | — |
| Morrison Briggs | Grant/Award from Employer | 24.6.2026 | 111,548 | +15,527 | — |
| Morrison Briggs | Grant/Award from Employer | 24.6.2026 | 22,714 | +22,714 | — |
| Kennedy Edward Moore Jr. | Grant/Award from Employer | 24.6.2026 | 54,957 | +15,527 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,711,553 shares short as of 2026-08-31 · vs. 3,995,358 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
57.1% of trading volume this week was short selling, vs. 73.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology